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Abstract 
Recent studies suggested a relation of homocysteine with lipid metabolism. Aim of this study 
was analyzing a possible genetic basis of such a relation in 504 individuals including 135 
consecutive Caucasian patients diagnosed with cerebrovascular disease as well as the patients’ 
healthy spouses (n = 100) and offspring (n = 269). We analyzed the association of plasma 
levels of lipoprotein a (Lpa), total cholesterol (TC), low density lipoprotein (LDL), high 
density lipoprotein (HDL), and triglycerides (TG) with plasma homocysteine levels and with 
seven variants of homocysteine metabolism: dihydrofolate reductase (DHFR) 
c.594+59del19bp, cystathionine beta-synthase (CBS) c.844_855ins68, methionine synthase 
(MTR) c.2756A>G, methylenetetrahydrofolate reductase (MTHFR) c.677C>T and 
c.1298A>C, reduced folate carrier 1 (RFC1) c.80G>A, and transcobalamin 2 (Tc2) c.776C>G. 
Linear regression analysis showed an association of Tc2 c.776C>G with LDL  (p = 0.010), 
HDL (p = 0.009) and TG (p = 0.007) with the G-allele of Tc2 c.776C>G associated with an 
unfavorable blood lipid profile. Moreover, the G-allele of Tc2 c.776C>G was associated with 
higher homocysteine plasma levels in the subgroup of patients (p = 0.013, one-way ANOVA). 
These data support the hypothesis that alterations of homocysteine metabolism and an 
unfavorable blood lipoprotein profile may have a common genetic basis. Such conditions may 
be relevant for studies investigating independent risk factors for vascular disease.  
 
 
  
3
Introduction 
Hyperhomocysteinemia and altered plasma lipid levels are considered to be independent risk 
factors for the development of vascular disease. Recent studies, however, suggested a relation 
of homocysteine and lipid metabolism [1]. Patients with severe hyperhomocysteinemia due to 
cystathionine β-synthase (CBS) deficiency (OMIM #236200) develop a wide range of 
symptoms including arteriosclerosis and hepatic steatosis (fatty degeneration of liver tissue) 
[2]. CBS-deficient mice also show hepatic steatosis associated with an abnormal lipid 
metabolism [3]. A correlation of plasma homocysteine levels with the blood lipid profile was 
found in patients with moderate hyperhomocysteinemia [4, 5] as well as in animal models [6, 
7] and cell cultures [8]. In wildtype and APOE-deficient mice, depletion of dietary folate (a 
cofactor of homocysteine metabolism) leads to increased levels of serum and liver cholesterol 
and altered expression profile of the cholesterol biosynthesis pathway [9]. A meta-analysis by 
Sharma et al demonstrated 112 genes that are modulated by elevated levels of homocysteine. 
Mapping these genes to their pathways suggested that hyperhomocysteinemia might induce 
arteriosclerosis by directly affecting the lipid metabolism [10]. To test for a possible 
interaction between homocysteine and plasma lipid metabolism on the genetic level, we 
examined seven functionally relevant genetic variants of homocysteine metabolism for a 
possible influence on the plasma lipid profile. 
 
Materials and Methods 
Patients and study participants 
Overall, 504 individuals were included in this study. We recruited 135 consecutive Caucasian 
patients (mean ± SD age, 64.2 ± 8.8 years, 27.4% female) from the ultrasound division of the 
Department of Neurology, University of Bonn, Germany. Patients had been referred due to 
cerebro-, cardiovascular or peripheral vascular disease and had been diagnosed with at least 
unilateral 30% carotid stenosis. Additionally, we recruited the patients’ spouses (n = 100; 61.8 
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± 8.7 years, 79% female) and their offspring (n = 269, 35.9 ± 8.4 years, 53% female). 
Personal data, ultrasonic findings, medical history, tobacco smoking and laboratory findings 
including fasting blood lipid profile parameters were determined as described previously [11]. 
Of the enrolled subjects, 17.9% received medication with a HMG-COA reductase inhibitor 
(statin). Patients with abnormal renal parameters or intake of (multi)vitamin preparations were 
excluded from the study. Data about physical activity or life-style were not available. The 
study was approved by the local ethics committee, and all participants gave written informed 
consent. 
 
Genotyping 
Genomic DNA prepared from peripheral leukocytes was used for genotyping by PCR 
amplification and restriction analysis of seven genetic variants of homocysteine metabolism 
including the intronic deletion dihydrofolate reductase (DHFR) c.594+59del19bp (affecting 
the transcript level; GenBank NM_000791.3), the splice alteration cystathionine beta-synthase 
(CBS) c.844_855ins68 (affecting the transcript level; GenBank S78267.1), and the missense 
mutations (i.e., leading to amino acid exchanges) methionine synthase (MTR) c.2756A>G 
(p.D919G; rs1805087), methylenetetrahydrofolate reductase (MTHFR) c.677C>T (p.A222V; 
rs1801133) and c.1298A>C (p.E429A; rs1801131), reduced folate carrier 1 (RFC1) c.80G>A 
(p.R27H; rs1051266 ), and transcobalamin 2 (Tc2) c.776C>G (p.P259R; rs1801198) [12]. 
 
Statistics 
Deviations from Hardy-Weinberg equilibrium were separately analyzed using a 2 goodness-
of-fit-test comparing observed and expected numbers for each genetic variant ( = 0.05). As 
some of the analyzed variables were not normally distributed, a log transformation was 
carried out for statistical testing. Linear regression with lipoprotein(a) (Lpa), total cholesterol 
(TC), LDL, HDL, and triglyceride (TG) fasting plasma levels as dependent variables and age, 
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gender, statin therapy, smoking, family relationship, and the seven examined polymorphisms 
as independent variables was utilized to test for independent associations of the 
polymorphisms with the plasma lipid profile. Due to multiple testing, threshold was defined 
as  = 0.01 in accordance to the Bonferroni-correction. Additionally, linear regression was 
used to analyze the association of homocysteine levels with the seven polymorphisms. One-
way ANOVA was used for univariate descriptive analysis of the association of genotypes with 
plasma lipoprotein parameters. 
 
Results  
The distribution of genotypes did not deviate from the Hardy-Weinberg equilibrium. Linear 
regression showed a correlation of the Tc2 c.776C>G polymorphism with the plasma levels of 
LDL (p = 0.010), HDL (p = 0.009), and TG (p = 0.007), when all study participants were 
analysed. Separate analysis for patients, spouses and offspring, and participants without 
arteriosclerosis yielded non-significant results (data not shown). TC plasma levels showed an 
association with the Tc2 c.776C>G polymorphism for trend (p=0.019). Lpa plasma levels 
were not associated with Tc2 c.776C>G. The MTHFR c.677C>T polymorphism correlated 
with HDL plasma levels (p = 0.008). None of the other polymorphisms analyzed was 
associated with the blood lipid profile.  
The plasma homocysteine level was associated with age (Beta = 0.312; p < 0.001), gender (p 
< 0.001), and with tobacco smoking (p = 0.012), but not with plasma lipoproteins. MTHFR 
c.677C>T was associated with the homocysteine plasma levels (MTHFR c.677CC: 
homocysteine = 12.90 μmol/l ± 4.00; MTHFR c.677CT: 13.65 μmol/l ± 4.02; MTHFR 
c.677TT: 15.20 μmol/l ± 5.37; p < 0.001). The G-allele of Tc2 c.776C>G was associated with 
higher homocysteine levels in the subgroup of patients (p=0.013, one-way ANOVA). None of 
the other polymorphisms analyzed was associated with the homocysteine level (data not 
shown). 
  
6
We found a correlation of gender with HDL (p < 0.001), and TG (p < 0.001) with women 
yielding higher HDL levels, and lower TG levels. Age correlated with TC (Beta=0.246; 
p<0.001), and LDL (Beta=0.206; p<0.001) with TC and LDL levels increasing with age. 
Group of study (patients, spouses or offspring) was also associated with TC (p < 0.001) and 
LDL (p < 0.001), but not with the other lipoprotein parameters. Separate group analysis 
(patients, spouses and offspring), showed that the G-allele of Tc2 c.776C>G was only 
associated with TC and LDL in the offspring, but not in patients or spouses or patients and 
spouses combined. Statin treatment correlated with TC (p=0.092), and LDL (p=0.033) only 
for trend.  
 
Discussion 
In our study sample, the G-allele of Tc2 c.776C>G was associated with an unfavorable blood 
lipoprotein profile, i.e. with higher LDL plasma levels, lower HDL plasma levels, higher 
triglyceride plasma levels and higher TC levels for trend. Additionally, MTHFR c.677C>T 
correlated with HDL plasma levels. As this polymorphism is a major polymorphic 
determinant of homocysteine plasma levels and is associated with vascular disease, this trend 
may be worthwhile to be retested in additional studies.  
The G-allele of Tc2 c.776C>G leads to the amino acid substitution p.P259R affecting the 
affinity of the transcobalamin2 to vitamin B12 and the ability to transport vitamin B12 into 
tissues [13-15]. The reported effects on homocysteine levels have been inconsistent [16, 17]. 
In our sample, the G-allele of Tc2 c.766C>G was associated with higher homocysteine plasma 
levels in the patient subgroup, but not in the whole study population. However, Tc2 c.766C>G 
has been reported to be associated with increased methylmalonic acid [17, 18], which is 
regarded as a very early indicator of functional vitamin B12 deficiency. This indicates a 
reduced intracellular homocysteine remethylation in association with the G-allele. Olzewski et 
al described a correlation between plasma homocysteine levels and TC, as well as TG plasma 
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levels in middle-aged, male probands. Treatment with vitamin B12, vitamin B6 and folic acid 
over 21 days significantly lowered homocysteine, but also TC, TG and LDL plasma levels in 
these individuals [19]. Recently, it was shown that experimentally induced 
hyperhomocysteinemia in rats leads to significantly increased plasma cholesterol levels 
accompanied by increased expression and activity of hepatic HMG-CoA reductase, a rate 
limiting enzyme in cholesterol biosynthesis [20-22]. In addition, it was demonstrated that 
homocysteine supplementation of yeast leads to an accumulation of S-adenosyl-homocysteine 
(SAH), which attenuates S-adenosyl-methionine (SAM)-dependent methyltransferase 
activities and results in an inhibition of phospholipid methylation and finally triacylglycerol 
accumulation [23].  
Therefore, the association of the G-allele of Tc2 c.677C>G with an unfavorable lipoprotein 
profile may be explained by functional vitamin B12 deficiency, and disturbed intracellular 
homocysteine and SAM metabolism [1]. 
 
The missing data about family relationship, physical activity, diet, and alcohol consumption 
are limitations of the present study. However, the results, although preliminary, suggest an 
intriguing genetic link between homocysteine and lipoprotein metabolism. Within the 
limitation of any association study and within the limitations given by restricted 
representativity of our study sample concerning the general population, these data support the 
hypothesis that homocysteine metabolism interacts with lipoprotein metabolism. The 
missense polymorphism Tc2 c.776C>G may be a common genetic basis of elevated 
homocysteine plasma levels and an unfavorable blood lipoprotein profile. The observed 
biochemical and genetic linkage of homocysteine and lipoprotein plasma levels may be of 
importance for studies investigating risk factors for vascular disease and should be confirmed 
in independent studies. 
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Tc2 c.776C>G 
CC 
(n=139) 
CG 
(n=229) 
GG 
(n=136) 
Linear Regression 
total blood 
cholesterol 
236 ± 48 
 
240 ± 45 
 
248 ± 48 
 
p=0.019 
 
LDL- 
Cholesterol  
154 ± 38 159 ± 40 
 
168 ± 42 p=0.010 
HDL-cholesterol  61 ± 18 60 ± 18  56 ± 15 p=0.009 
 
Triglycerides 100 ± 65 105 ± 60 120 ± 83 p=0.007 
 
Lipoprotein a 34 ± 39 30 ± 32 32 ± 34 p=0.652 
 
 
Table 1: Linear regression with TC, LDL, HDL, TG, and Lpa fasting plasma levels (mg/dl) as 
dependent variables and Tc2 c.776C>G (the other polymorphisms are not shown). Due to 
multiple testing (five different plasma lipid levels), threshold was defined as =0.01. Values 
are shown as mean plasma level values in mg/dl  standard deviation for each TC2 genotype. 
All individuals were included in this analysis. 
 
 
